

কর্মায়ার্বা রাজন্য থাঁমা নিগম (গম তর বাঁড়নায় মঁরালয়, মারে মংকার) EMFLOYEES'STATE INSURANCE CORPORATION (Ministryof Labour & Employment, Govt. of India)



U-25/12/ATR/NSQ/2024-MedV(E-741817)

Dated: 11.12.2024

ORDER

<u>Subject</u>: Debarring of firm M/s Sai Parenterals Pvt. Ltd for drug (Heparin Sodium Inj:- Each ml to contain: Heparin Sod. 5000 IU, 5ml Vial)-reg.

ESIC has a system of formulation of DG ESIC Rate Contracts for Drugs & Dressings through open e-tenders. ESIC and ESIS Institutions procure Drugs as per their requirement through Central Rate Contracts for providing drugs to ESI Beneficiaries. Drugs are being procured and ESI Institutions strictly monitor the quality of supplied drugs in adherence to the quality control clauses of DG ESIC Tender Enquiries.

Two instances of NSQ (Not of Standard Quality) were reported for the Item under category "B" as detailed below supplied by firm M/s Sai Parenterals Pvt. Ltd: -

S. No.	Name of Pharmaceutical Firm (M/s)	Details of Drugs
1.	Sai Parenterals Pvt. Ltd.	Item Name: Heparin Sodium Inj:- Each ml to contain: Heparin Sod. 5000 IU, 5ml Vial
		Item No.:71
		RC No.:143C

Show Cause Notices were issued to the firm on 17.10.2022 and 22.08.2023 and reminder show cause notice on 22.05.2024 giving ample opportunity to explain as to why action should not be taken against M/s Sai Parenterals Pvt. Ltd as per Terms & Conditions of the Tender Enquiry. However, M/s Sai Parenterals Pvt. Ltd has not submitted the requisite documents within prescribed time as per Terms & Conditions of the Tender Enquiry.

Contd. to pre-page:

The case was evaluated by ESIC and as per Clause No. 14 (QUALITY CONTROL) of Tender Enquiry 143C, M/s Sai Parenterals Pvt. Ltd stand debarred with immediate effect from participating in future tenders of all ESI Institution for the above-mentioned drug (Heparin Sodium Inj: - Each ml to contain: Heparin Sod. 5000 IU, 5ml Vial) for a period of 02 years prospectively from the date of issuance of this order along with forfeiture of Performance Security deposit of the said NSQ drug(s).

This issue with the approval of Director General, ESI Corporation.

With regards,

Signed by Neeta Garbiyal Date: 11-12-2024 10:09:33

Dy. Medical Commissioner (RC)

Copy to:

- 1. All ESIC/ESIS Institution for information and necessary action.
- 2. Central Drugs Standard Control Organization, DGHS, MoH&FW, Government Of India, FDA Bhavan, ITO Kotla Road, New Delhi-110002, dci@nic.in
- 3. Drug Control Bhavan, Drug Control Administration, Head Quarters, 79, Vengal Rao Nagar, Hyderabad-500038, Email:dg_dca@telngana.gov.in, dcatelangana@gmail.com.
- CDSCO Zonal Office, Hyderabad, CDSCO Bhavan T.B. & Demonstration Centre, S.R. Nagar, Hyderabad-500038.AP. Email: Hyderabad@cdsco.nic.in.
- M/s Sai Parenterals Pvt.Ltd.,8-2-700, Srida Anushka Pride, Road No. 12,Banjara hills, Hyderabad-500034, Telangana. Email: md.saiparenterals@gmail.com, saiparenterals@gmail.com.
- 6. Website Content Manager for uploading on Website.
- 7. Guard File.